VANCOUVER, Jun 16, 2014 - West Point Resources Inc. (TSX VENTURE:WPO) (the "Company") is pleased to announce it has finalized a definitive agreement with Cannabix Breathalyzer Inc to license the North American Rights to the Cannabix Marijuana Breathalyzer. The Company also reports that it has received conditional approval from the Canadian Securities Exchange (CSE) for its listing application. West Point is also currently completing a concurrent private placement financing.
Mr. Kal Malhi and Dr. Raj Attariwala from Cannabix Breathalyzer Inc will be joining West Point's management team and will guide the development of the marijuana breathalyzer system. Dr. Bruce Goldberger from the University of Florida is also joining as a Senior Advisor.
West Point's drug-impairment recognition system is starting to receive local media attention and has recently been featured on CTV news, The Province, and The Delta Optimist. Several other local and international media outlets have expressed interest in providing media coverage for the marijuana breathalyzer product being developed by West Point and interviews will be scheduled over the coming weeks.
We seek Safe Harbor.
On behalf of the Board of Directors
Rav Mlait President and CEO
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Für den Inhalt des Beitrages ist allein der Autor verantwortlich bzw. die aufgeführte Quelle. Bild- oder Filmrechte liegen beim Autor/Quelle bzw. bei der vom ihm benannten Quelle. Bei Übersetzungen können Fehler nicht ausgeschlossen werden. Der vertretene Standpunkt eines Autors spiegelt generell nicht die Meinung des Webseiten-Betreibers wieder. Mittels der Veröffentlichung will dieser lediglich ein pluralistisches Meinungsbild darstellen. Direkte oder indirekte Aussagen in einem Beitrag stellen keinerlei Aufforderung zum Kauf-/Verkauf von Wertpapieren dar. Wir wehren uns gegen jede Form von Hass, Diskriminierung und Verletzung der Menschenwürde. Beachten Sie bitte auch unsere AGB/Disclaimer!